Loading...
01/11 13:56
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed financial performance, with declining revenue and increasing losses, despite some positive aspects like consumables growth and cost reduction plans. The Q&A highlights concerns about declining large projects and economic pressures, while management's vague responses add uncertainty. The 2025 guidance shows modest growth expectations, but the lack of strong financial performance and cautious market environment suggest a negative stock reaction.
Revenue $30.3 million, a decline of 5% year-over-year due to pressure on capital equipment and a decline in large multimillion-dollar projects from pharma customers.
Consumables Revenue $18.1 million, up 6% year-over-year driven by strong performance from products launched in the past 12 months.
Instrument Revenue $2.6 million, up 3% year-over-year, reflecting continued pressure on capital equipment.
Accelerator Lab Revenue $5.6 million, a decrease of 36% year-over-year, driven by a decline in large multimillion-dollar projects from pharma customers.
GAAP Gross Profit $16.4 million with a margin of 54.1%, reflecting a decrease of 150 basis points year-over-year primarily due to a non-cash charge to inventory reserves.
Non-GAAP Gross Profit $15.1 million with a non-GAAP gross margin of 49.7%, a decrease of 150 basis points year-over-year primarily driven by a non-cash charge to inventory reserves.
GAAP Operating Expenses $42.8 million, up $9.1 million year-over-year, including approximately $7 million of costs related to acquisition and integration expenses.
Non-GAAP Operating Expenses $33.8 million, up $2.3 million year-over-year.
Adjusted EBITDA Loss of $11.3 million, compared to a loss of $8.1 million in the prior year, including investments in Simoa ONE and Alzheimer’s diagnostics.
Cash Balance $269.5 million, down $22.2 million year-over-year, with $13.2 million applied towards one-time items.
Adjusted Cash Burn $9 million, a reduction of over 50% compared to adjusted cash burn of $19.4 million in the prior year.
New Product Launches: In Q1, Quanterix launched four new immunology assays, building on the 20 new assays introduced last year.
Simoa ONE Launch: Quanterix is on track to release the Simoa ONE instrument and reagent platform by year-end, which will deliver up to 10x the sensitivity of existing systems.
LucentAD Complete Test: Quanterix anticipates introducing pricing for the LucentAD Complete test, a multi-marker algorithm-driven Alzheimer’s risk assessment tool, later this summer.
Market Expansion through Akoya Merger: The equity value of the Akoya merger is reduced from $201 million to $66 million, increasing Quanterix’s ownership from 70% to 84%.
Expansion into Immunology and Oncology: Quanterix is expanding its addressable market from $1 billion to $5 billion through the Akoya acquisition.
Collaboration with ARUP Laboratories: Quanterix expanded its footprint in Alzheimer’s diagnostics through a collaboration with ARUP Laboratories to offer the pTau217 blood test.
Operational Efficiencies: Quanterix announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026.
Cash Usage Improvement: Adjusted cash burn during Q1 was $9 million, a reduction of over 50% compared to the prior year.
Strategic Focus on Neurology, Immunology, and Oncology: Quanterix is committed to driving advancements in high-sensitivity protein detection and expanding into critical therapeutic areas.
Democratizing Access to Technology: Starting in 2026, Quanterix will allow customers to use unlocked Simoa ONE assay kits on over 20,000 existing flow cytometers.
Market Environment: The company is facing market headwinds due to reduced academic funding and biopharma spending, which may impact revenue growth.
Regulatory Issues: There is a potential impact of tariffs on incoming materials, which could affect gross margins.
Supply Chain Challenges: The company anticipates a 20% reduction in NIH funding levels, which could lead to additional revenue pressure.
Competitive Pressures: The Accelerator lab revenue has decreased significantly, driven by a decline in large multimillion-dollar projects from pharma customers, indicating a cautious approach from biopharma and biotech customers.
Economic Factors: The overall economic environment is leading to conservatism among customers, resulting in project delays and smaller ticket sizes.
Strategic Initiatives: 1. Launch of four new immunology assays in Q1, building on 20 new assays from last year, contributing to highest consumables revenue quarter. 2. Expansion into adjacencies with the upcoming Simoa ONE platform, expected to deliver up to 10x sensitivity and improved specificity. 3. Progress in Alzheimer’s diagnostics with new collaborations and upcoming pricing for LucentAD Complete test.
Merger with Akoya Biosciences: Amended transaction reduces equity value from $201 million to $66 million, increasing Quanterix’s ownership from 70% to 84%. Expected contribution from Akoya is 37% to top line and 40% to gross profit.
Revenue Guidance: Expected revenue for 2025 is $120 million to $130 million, reflecting a decline of 5% to 13%.
Gross Margin Guidance: GAAP gross margin expected to be 55% to 59%, non-GAAP gross margin 50% to 54%, a reduction of 300 basis points from prior guidance.
Cash Flow Outlook: Expect to achieve positive cash flow by 2026 with a cash balance exceeding $100 million.
Cost Reduction Initiatives: Announced $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026.
Shareholder Return Plan: Quanterix announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026. This is part of their strategy to achieve positive cash flow by 2026, supported by a balance sheet exceeding $100 million.
Shareholder Ownership: The equity value of the pending merger with Akoya Biosciences has been reduced by 67%, increasing Quanterix’s shareholder ownership of the combined company from 70% to 84%.
The earnings call summary shows mixed signals. The company has optimistic guidance and potential market expansion, but faces current financial challenges with losses and reduced cash position. The Q&A highlights concerns about government shutdown impact, market uncertainties, and lack of specific guidance. Despite these, there are positive notes on synergies, Medicare traction, and cross-selling opportunities. However, the lack of guidance and financial losses balance out the positives, leading to a neutral sentiment.
The earnings call reveals significant challenges, including a substantial revenue decline, goodwill impairment, and increased operational expenses. Despite some positive developments like a rise in sales to diagnostics partners, the overall financial performance is concerning, with a notable loss in adjusted EBITDA. The Q&A section suggests some optimism but also highlights ongoing market uncertainties and dependence on external conditions. The strategic initiatives and cost reductions may offer future benefits, but current financial metrics and guidance indicate a negative outlook for the stock price in the short term.
The earnings call reveals mixed financial performance, with declining revenue and increasing losses, despite some positive aspects like consumables growth and cost reduction plans. The Q&A highlights concerns about declining large projects and economic pressures, while management's vague responses add uncertainty. The 2025 guidance shows modest growth expectations, but the lack of strong financial performance and cautious market environment suggest a negative stock reaction.
The earnings call reveals several concerning factors: a decline in overall revenue, increased operating expenses, and a wider adjusted EBITDA loss. Although there are positive aspects like strong consumables revenue and cost-saving measures, the weak guidance for 2025 and uncertainties surrounding large projects and FDA submissions weigh heavily. The Q&A section further highlights these uncertainties, with management's vague responses not alleviating concerns. Without a clear path to growth and profitability, the stock is likely to experience a negative reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
